Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the drug registration application of Tetracaine Hydrochloride Gel was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The application was submitted by Shanghai Zhaohui Pharmaceutical, a unit of the pharmaceutical firm.
The drug is intended to be used as a percutaneous local anaesthetic for the skin prior to venepuncture or venous cannulation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments